On 19 March, Alzheimer Europe (AE) hosted a Company Round Table meeting in Brussels. The meeting was a hybrid event, with many participants attending in person and some joining remotely. It was attended by company representatives from Biogen, Bristol Myers Squibb, Eli Lilly, EFPIA, Essity, GE Healthcare, Grifols, Novo Nordisk, Nutricia, Prothena, Roche, members of the AE staff and members of the AE Board. During the meeting, four speakers provided updates on recent policy and research developments.
First, Cindy Birck, AE Project Officer, gave an update on our Clinical Trials Watch, an online database providing accessible and up-to-date information on clinical trials that are investigating drugs for Alzheimer’s disease and/or dementia. Next, Owen Miller, AE Project Officer, shared some updates on EU policy developments, European Parliament elections and AE European Parliament election campaign. Alexandra Tamas, Director for Public Affairs at EFPIA, gave then a talk on the EU Pharmaceutical Legislation and provided an update on the discussions at the European Parliament and Member States.
Finally, Jean Georges, AE Executive Director, informed participants about Alzheimer Europe’s activities in 2024 including projects and the upcoming annual conference to be held from 8 to 10 October in Geneva, Switzerland, under the motto "New horizons – Innovating for dementia". We would like to thank our sponsors and members for participating in this meeting and we look forward to welcoming them to the next Company Round Table meeting in June in Luxembourg.
